Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and BiomarkersYakun Wang, Lin Shen, Yunpeng Liu et al.|The Oncologist|2022Cited by 15